Universe Pharmaceuticals INC — Proxy Solicitation & Information Statement 2025

Jan 30, 2025

6-K 1 ea0229115-6k_universe.htm CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

___

FORM 6-K

___

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2025

Commission file number: 001-40231

___

Universe Pharmaceuticals INC

___

265 Jingjiu Avenue Jinggangshan Economic and Technological Development Zone Ji’an, Jiangxi, China 343100 +86-0796-8403309 (Address of principal executive offices)

___

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 4 0-F.

Form 20 -F ☒ Form 40 -F ☐

In connection with an Extraordinary General Meeting of Shareholders of Universe Pharmaceuticals INC, a company incorporated under the laws of the Cayman Islands (the “Company”), the Company hereby furnishes the following documents:

Exhibits

Exhibit No.	Description
99.1	Notice and Proxy Statement of Extraordinary General Meeting of Shareholders, dated January 30, 2025, to be mailed to the shareholders of the Company in connection with the Extraordinary General Meeting of Shareholders of the Company
99.2	Form of Proxy Card to be mailed to shareholders of the Company for use in connection with the 2025 Extraordinary General Meeting of Shareholders of the Company

1

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

/s/ Gang Lai
Gang Lai
Chief Executive Officer

2